U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564466) titled 'A Study of SKB571 in Participants With Gastrointestinal Tumors' on April 14.
Brief Summary: This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Gastrointestinal Tumors
Intervention:
DRUG: SKB571 for injection
Intravenous(IV) infusion(Q3W)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Dail...